Novartis Ag

Other

Novartis Pharma Gmbh

Fabrizio Gasparini

Yves Auberson

Baltazar Gomez-Mancilla

Silvio Ofner

Donald Johns

Ricardo Carl Elciario Dolmetsch

Hans Allgeier

Dominik Feuerbach

Nicholas David Cosford

Simon Mensah Ametamey

Michel Biollaz

Roland Heckendorn

Terance William Hart

Eveline Schaadt

Markus Waldhuber

Edwin Carl Johnson

Nathalie George

Rainer Kuhn

Rainer Wilcken

G&ouml;n&uuml;l Veli&ccedil;elebi

Mark Andrew Varney

Derya Shimshek

Honnappa Srinivas

Lea Kessler

Kaspar Zimmerman

Verena Brand

Daniel Umbricht

Hans-Jürgen Pfannkuche

Thérése Di Paolo

Marie-Laure Rouzade-Dominguez

The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol use disorder.

Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use

The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.

Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use

The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

TREM2 stabilizing antibodies

The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.

Combination products

The present invention relates to novel pyridylacetylene derivatives of formula I their preparation, their use as radio-traces/markers and compositions containing them.

Pyridylacetylenes for use as radiotracers and imaging agents

The invention provides compounds of formula I wherein n, A, R, R', R&#x2033;, R, X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.

Acetylene derivatives having MGluR 5 antagonistic activity

The invention provides compounds of formula (I) wherein m, n, A, R, R', R&#x2033;, R, X and Y are as defined in the description, and their preparation. The compounds of formula (I) are useful as pharmaceuticals in the treatment of e.g. nervous system disorders 

Acetylene derivatives having mGluR 5 antagonistic activity

Pyridine derivatives

Growing community of inventors

Lausen, Switzerland

Fabrizio Gasparini